Symbols

CV

CapsoVision·NASDAQ

--(--)

CV fundamentals

CV Q4 2025 Earnings

CapsoVision (CV) released its earnings on Mar 26, 2026: revenue was 4.40M (YoY --), beat estimates; EPS was -0.12 (YoY --), beat estimates.

Revenue / YoY

4.40M

EPS / YoY

-0.12

Report date

Mar 26, 2026

CV Earnings Call Summary for Q4,2025

Revenue Momentum: 15% YoY growth driven by CapsoCam Plus adoption, 21% new account expansion.
AI Innovation: AI-assisted reading module submission to enhance diagnostic efficiency.
Pipeline Progress:
- CapsoCam Colon Gen 2 on track for Q3 2026 FDA submission, targeting late 2027 launch.
- Pancreatic cancer study (60-90 patients) to establish non-invasive screening criteria.
Financial Resilience: $14M capital raise supports R&D and commercial growth, with $10.1M cash post-Q4.

Earnings

EPS

Revenue

Revenue & Expenses

CV has released its 2025 Q4 earnings report, with revenue of 3.92M, reflecting a YoY change of 13.50%, and net profit of -7.39M, showing a YoY change of -59.39%. The Sankey diagram below clearly presents CV's revenue sources and cost distribution.

Key Indicators

CapsoVision (CV) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

CapsoVision (CV)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

CapsoVision (CV)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

CapsoVision (CV)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown